日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.

应用药代动力学/药效学模型连接小鼠抗肿瘤疗效和猴子毒理学数据,以确定白细胞介素-10 Fc融合蛋白的治疗指数

Yang Zheng, Loy James, Poirson Brian, Dai Yanshan, Rajendran Surendran, Xu Shihua, Spires Vanessa, Gururajan Murali, Lin Zheng, Arbanas Jaren, Carl Stephen, Pace Samantha, Wang Yun, Mehl John, Vasudevan Krishna, Spires Thomas, Novosiadly Ruslan, Coker Shodeinde, Perez Raymond, Covello Kelly, Morin Paul, Graziano Robert, Broz Miranda, Lehman-McKeeman Lois

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement

继续扩大入组标准,使临床试验更具代表性和包容性:ASCO-癌症研究之友联合研究声明

Kim, Edward S; Uldrick, Thomas S; Schenkel, Caroline; Bruinooge, Suanna S; Harvey, R Donald; Magnuson, Allison; Spira, Alexander; Wade, James L; Stewart, Mark D; Vega, Diana Merino; Beaver, Julia A; Denicoff, Andrea M; Ison, Gwynn; Ivy, S Percy; George, Suzanne; Perez, Raymond P; Spears, Patricia A; Tap, William D; Schilsky, Richard L

Physical activity and quality of life of patients with rheumatoid arthritis at the time of COVID-19 lockdown: an online patient survey

新冠疫情封锁期间类风湿性关节炎患者的身体活动和生活质量:一项在线患者调查

Lévy-Weil, Florence E; Jousse-Joulin, Sandrine; Tiffreau, Vincent; Perez, Raymond; Morisseau, Valentin; Bombezin-Domino, Alexis; Flipo, René-Marc

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

一项Ib/II期临床试验,评估首创抗CXCR4抗体Ulocuplumab联合来那度胺或硼替佐米加地塞米松治疗复发性多发性骨髓瘤的疗效

Ghobrial, Irene M; Liu, Chia-Jen; Redd, Robert A; Perez, Raymond P; Baz, Rachid; Zavidij, Oksana; Sklavenitis-Pistofidis, Romanos; Richardson, Paul G; Anderson, Kenneth C; Laubach, Jacob; Henrick, Patrick; Savell, Alexandra; Reyes, Kaitlen; Hornburg, Kalvis; Chuma, Stacey; Sabbatini, Peter; Robbins, Michael D; Becker, Pamela S

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

更正:CXCR1/2抑制剂瑞帕瑞辛在可手术HER-2阴性乳腺癌中的机会窗口试验

Goldstein, Lori J; Perez, Raymond P; Yardley, Denise; Han, Linda K; Reuben, James M; Gao, Hui; McCanna, Susan; Butler, Beth; Ruffini, Pier Adelchi; Liu, Yi; Rosato, Roberto R; Chang, Jenny C

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

米尔维妥昔单抗索拉夫坦辛(IMGN853,一种靶向叶酸受体α的抗体药物偶联物)在铂类耐药卵巢癌、输卵管癌或原发性腹膜癌中的安全性和活性:一项I期扩展研究

Moore, Kathleen N; Martin, Lainie P; O'Malley, David M; Matulonis, Ursula A; Konner, Jason A; Perez, Raymond P; Bauer, Todd M; Ruiz-Soto, Rodrigo; Birrer, Michael J

Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials

申办方和研究人员对当前肿瘤试验中研究性新药安全性报告流程的看法

Perez, Raymond; Archdeacon, Patrick; Roach, Nancy; Goodwin, Robert; Jarow, Jonathan; Stuccio, Nina; Forrest, Annemarie

Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project

临床试验电子门户加速安全性报告:临床试验转型计划研究性新药安全推进项目的建议

Perez, Raymond P; Finnigan, Shanda; Patel, Krupa; Whitney, Shanell; Forrest, Annemarie

Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment

源自143B骨肉瘤细胞的细胞外膜囊泡含有促破骨细胞生成物质:骨肉瘤骨微环境中一种新型的通讯机制

Garimella, Rama; Washington, Laurie; Isaacson, Janalee; Vallejo, Julian; Spence, Madoka; Tawfik, Ossama; Rowe, Peter; Brotto, Marco; Perez, Raymond

Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer

亚洲人群中化疗放疗诱发急性食管炎的发生率较低:一项针对不可切除的III期非小细胞肺癌已发表临床试验的荟萃分析

Komiya, Takefumi; Palla, Shana L; Wang, Feng; Perez, Raymond P; Huang, Chao H